PH12015500807A1 - Tgf�-derived polypeptides and uses thereof - Google Patents
Tgf�-derived polypeptides and uses thereofInfo
- Publication number
- PH12015500807A1 PH12015500807A1 PH12015500807A PH12015500807A PH12015500807A1 PH 12015500807 A1 PH12015500807 A1 PH 12015500807A1 PH 12015500807 A PH12015500807 A PH 12015500807A PH 12015500807 A PH12015500807 A PH 12015500807A PH 12015500807 A1 PH12015500807 A1 PH 12015500807A1
- Authority
- PH
- Philippines
- Prior art keywords
- tgfb
- diseases
- alk5
- interact
- ability
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 abstract 3
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120158A CU24181B1 (es) | 2012-11-09 | 2012-11-09 | POLIPÉPTIDOS DERIVADOS DEL TGFß |
| PCT/CU2013/000007 WO2014071894A1 (es) | 2012-11-09 | 2013-10-30 | POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015500807A1 true PH12015500807A1 (en) | 2015-06-08 |
Family
ID=49765213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015500807A PH12015500807A1 (en) | 2012-11-09 | 2015-04-13 | Tgf�-derived polypeptides and uses thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9701730B2 (enExample) |
| EP (1) | EP2918284B1 (enExample) |
| JP (2) | JP6298823B2 (enExample) |
| KR (1) | KR102093494B1 (enExample) |
| CN (1) | CN104902916B (enExample) |
| AR (1) | AR093391A1 (enExample) |
| AU (1) | AU2013344022B2 (enExample) |
| BR (1) | BR112015010145B1 (enExample) |
| CA (1) | CA2887455C (enExample) |
| CL (1) | CL2015001252A1 (enExample) |
| CO (1) | CO7400865A2 (enExample) |
| CU (1) | CU24181B1 (enExample) |
| EA (1) | EA031990B1 (enExample) |
| ES (1) | ES2857176T3 (enExample) |
| IL (1) | IL238621B (enExample) |
| JO (1) | JO3502B1 (enExample) |
| MX (1) | MX366060B (enExample) |
| MY (1) | MY173078A (enExample) |
| NZ (1) | NZ707850A (enExample) |
| PE (1) | PE20150890A1 (enExample) |
| PH (1) | PH12015500807A1 (enExample) |
| SG (1) | SG11201502980VA (enExample) |
| TN (1) | TN2015000129A1 (enExample) |
| TW (1) | TWI615404B (enExample) |
| UA (1) | UA115678C2 (enExample) |
| WO (1) | WO2014071894A1 (enExample) |
| ZA (1) | ZA201504462B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL423203A1 (pl) * | 2017-10-19 | 2019-04-23 | Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia | Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018094173A1 (en) * | 2016-11-18 | 2018-05-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling |
| CN119285746A (zh) * | 2024-10-24 | 2025-01-10 | 湖南中晟全肽生物科技股份有限公司 | 作为TGF-β受体激动剂肽的化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1087998A1 (en) * | 1998-06-16 | 2001-04-04 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| AU778998B2 (en) | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
| US6677432B1 (en) * | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| CA2575278A1 (en) * | 2004-06-30 | 2006-01-19 | Molecular Logix, Inc. | Epidermal growth factor receptor antagonists and methods of use |
| US7795389B2 (en) * | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| CN101365712A (zh) * | 2005-01-11 | 2009-02-11 | 莫勒丘尔洛吉克斯有限公司 | Pan-HER拮抗剂及其使用方法 |
| GB0724051D0 (en) * | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
| CA2796706A1 (en) * | 2010-04-22 | 2011-10-27 | The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center | High affinity leptins and leptin antagonists |
-
2012
- 2012-11-09 CU CU20120158A patent/CU24181B1/es active IP Right Grant
-
2013
- 2013-10-30 EP EP13805228.7A patent/EP2918284B1/en not_active Not-in-force
- 2013-10-30 US US14/440,627 patent/US9701730B2/en not_active Expired - Fee Related
- 2013-10-30 NZ NZ707850A patent/NZ707850A/en not_active IP Right Cessation
- 2013-10-30 WO PCT/CU2013/000007 patent/WO2014071894A1/es not_active Ceased
- 2013-10-30 EA EA201590914A patent/EA031990B1/ru not_active IP Right Cessation
- 2013-10-30 CA CA2887455A patent/CA2887455C/en active Active
- 2013-10-30 MY MYPI2015701369A patent/MY173078A/en unknown
- 2013-10-30 BR BR112015010145-3A patent/BR112015010145B1/pt active IP Right Grant
- 2013-10-30 ES ES13805228T patent/ES2857176T3/es active Active
- 2013-10-30 MX MX2015005875A patent/MX366060B/es active IP Right Grant
- 2013-10-30 AU AU2013344022A patent/AU2013344022B2/en not_active Ceased
- 2013-10-30 CN CN201380058181.7A patent/CN104902916B/zh not_active Expired - Fee Related
- 2013-10-30 PE PE2015000549A patent/PE20150890A1/es not_active Application Discontinuation
- 2013-10-30 UA UAA201505566A patent/UA115678C2/uk unknown
- 2013-10-30 SG SG11201502980VA patent/SG11201502980VA/en unknown
- 2013-10-30 JP JP2015540045A patent/JP6298823B2/ja not_active Expired - Fee Related
- 2013-10-30 KR KR1020157011131A patent/KR102093494B1/ko active Active
- 2013-11-03 JO JOP/2013/0317A patent/JO3502B1/ar active
- 2013-11-07 AR ARP130104078A patent/AR093391A1/es active IP Right Grant
- 2013-11-07 TW TW102140494A patent/TWI615404B/zh not_active IP Right Cessation
-
2015
- 2015-04-03 TN TNP2015000129A patent/TN2015000129A1/fr unknown
- 2015-04-13 PH PH12015500807A patent/PH12015500807A1/en unknown
- 2015-04-28 CO CO15095702A patent/CO7400865A2/es unknown
- 2015-05-04 IL IL238621A patent/IL238621B/en not_active IP Right Cessation
- 2015-05-08 CL CL2015001252A patent/CL2015001252A1/es unknown
- 2015-06-08 ZA ZA2015/04462A patent/ZA201504462B/en unknown
-
2018
- 2018-02-26 JP JP2018031896A patent/JP6608473B2/ja not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL423203A1 (pl) * | 2017-10-19 | 2019-04-23 | Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia | Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII |
| PL238850B1 (pl) * | 2017-10-19 | 2021-10-11 | Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia | Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY162324A (en) | Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections | |
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| BR112014029966A2 (pt) | proteínas de fator de crescimento de fibroblasto 21 | |
| BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| WO2014176373A3 (en) | Interleukin-10 compositions and uses thereof | |
| WO2017044894A3 (en) | Cartilage-homing peptides | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| IN2014DN06920A (enExample) | ||
| MX378431B (es) | Uso terapèutico de proteìnas morfogenèticas òseas. | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| EA201300592A1 (ru) | Ингибиторы апоптоза и их применение | |
| EA201690659A1 (ru) | Композиции аморфного магнийзамещенного фосфата кальция и их применение | |
| GB201118201D0 (en) | Novel peptides | |
| PH12015500807A1 (en) | Tgf�-derived polypeptides and uses thereof | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| MX352456B (es) | Lotes de adenovirus recombinantes con extremos alterados. | |
| IT201700009222A1 (it) | Composizione per la preparazione del paziente per la colonscopia virtuale |